SS-31 Heart Failure Research: Mitochondrial Peptide Mechanisms and Clinical Evidence

SS-31 (elamipretide) is a cardiolipin-targeting mitochondrial peptide that reached Phase 2/3 clinical trials in heart failure. PROGRESS-HF Phase 2 showed improved functional outcomes in HFpEF. Barth syndrome trials showed significant mitochondrial disease benefit. Phase 3 (VITALITY-HFpEF) was interrupted due to Stealth BioTherapeutics' bankruptcy. The compound remains a leading research tool for mitochondrial pharmacology. See SS-31 guide and SS-31 cardiolipin deep dive.

Cardiolipin: A unique phospholipid found almost exclusively in the inner mitochondrial membrane. Essential for structural organization of ETC complexes (I, III, IV) and respiratory supercomplex formation. Its oxidation severely impairs mitochondrial energy production.

Inner mitochondrial membrane (IMM): The highly folded inner membrane where oxidative phosphorylation occurs. ETC complexes are embedded in the IMM; cardiolipin is a critical structural component.

Cristae: The folded IMM structures that increase surface area for oxidative phosphorylation. Cristae organization is cardiolipin-dependent.

ETC (electron transport chain): The series of protein complexes (I-IV) that transfer electrons to drive the proton gradient powering ATP synthase.

HFpEF (heart failure with preserved ejection fraction): Heart failure with normal or near-normal ejection fraction but impaired filling and reduced exercise capacity. Mitochondrial dysfunction is a key pathological feature.

Elamipretide: The INN for SS-31, also known as MTP-131. Developed by Stealth BioTherapeutics.

The heart consumes more oxygen per gram than any other tissue. Cardiomyocytes contain 5,000-8,000 mitochondria per cell. In heart failure, this system is disrupted: cardiolipin oxidation from elevated mitochondrial ROS causes ETC complex dissociation, cristae remodeling, and impaired respiration. Published research shows significantly reduced cardiolipin content in failing human hearts.

Cytochrome c release is also cardiolipin-dependent. Normally bound to cardiolipin on the IMM, cytochrome c detaches when cardiolipin is oxidized and can initiate cardiomyocyte apoptosis, contributing to progressive cardiomyocyte loss in chronic heart failure.

For broader mitochondrial biology context, see mitochondria and aging research and SS-31 cardiolipin deep dive.

SS-31's mechanism was identified by Hazel Szeto and colleagues at Cornell. SS-31 is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) with alternating aromatic and basic amino acids, giving it high affinity for cardiolipin.

SS-31 binds directly to cardiolipin in the IMM. This binding prevents cardiolipin oxidation (through the antioxidant Dmt residue), preserves ETC complex organization, maintains cytochrome c oxidase activity, and prevents cytochrome c detachment from the IMM.

Published data shows SS-31 treatment restores mitochondrial membrane potential, reduces ROS, improves state 3 respiration (ADP-stimulated ATP production), and prevents cytochrome c release in stressed cardiomyocytes.

See SS-31 cardiolipin deep dive and SS-31 clinical evidence.

PROGRESS-HF was a Phase 2, randomized, double-blind, placebo-controlled study of subcutaneous elamipretide in HFpEF patients. HFpEF was selected because mitochondrial dysfunction is particularly prominent in this subtype and established pharmacological treatments are limited.

Key findings: the primary endpoint of 6-minute walk distance showed favorable separation between elamipretide and placebo groups, with improved exercise capacity in the treatment arm. Biomarker analyses showed favorable changes in myocardial stress and fibrosis markers (NT-proBNP trends, IGFBP-7). Injection site reactions were the most common adverse event; tolerability was generally good.

Phase 2 results were considered encouraging enough to justify Phase 3 development, leading to VITALITY-HFpEF.

Barth syndrome is a rare X-linked mitochondrial cardiomyopathy caused by tafazzin mutations impairing cardiolipin remodeling, making it a genetically defined model for cardiolipin-targeted therapy.

The TAZPOWER trial of elamipretide in Barth syndrome demonstrated significant improvement in skeletal muscle function (6-minute walk distance and handgrip strength) with a favorable safety profile. This trial provides the clearest mechanism-to-outcome evidence for SS-31: the intervention directly targeted the cardiolipin pathology caused by the genetic defect.

LICA trial examined SS-31 in Leber's Hereditary Optic Neuropathy (LHON), another primary mitochondrial disease involving Complex I dysfunction. Early data showed some visual acuity benefit.

VITALITY-HFpEF was designed to confirm PROGRESS-HF Phase 2 findings in a larger, more statistically powered sample. Primary endpoint: 6-minute walk distance, with patient-reported functional status outcomes.

Phase 3 is required because Phase 2 trials are powered for signal detection, not definitive efficacy conclusions. PROGRESS-HF's positive trend needed confirmation with appropriate statistical power across the heterogeneous HFpEF population.

The scientific questions: whether SS-31's cardiolipin mechanism produces clinically meaningful functional improvement in HFpEF; whether Phase 2 biomarker improvements correlate with patient outcomes; and whether treatment is effective across heterogeneous HFpEF.

Stealth BioTherapeutics filed for bankruptcy protection in 2022. The company faced mounting financial challenges from the high cost of clinical development, the challenging commercial pathway for SC-administered heart failure treatment, and broader biotech market conditions.

VITALITY-HFpEF was discontinued before completing full enrollment. Partial Phase 3 data was analyzed but did not meet the primary endpoint in the enrolled population, though interpretation is complicated by the interrupted trial design.

No other company has publicly acquired elamipretide's development rights and resumed clinical trials. The clinical development interruption was driven by commercial factors rather than safety signals.

See SS-31 guide, SS-31 clinical evidence, and mitochondria and aging research.

Despite the clinical development interruption, SS-31 remains one of the most important research tools in mitochondrial pharmacology. Published data establishes: the cardiolipin-targeting mechanism is pharmacologically tractable; SS-31 reaches mitochondria after systemic administration; cardiolipin stabilization produces measurable functional consequences; and the compound is well tolerated in humans.

Complementary mitochondrial research compounds: MOTS-c (AMPK-mediated metabolic signaling) and NAD+ (mitochondrial electron carrier and sirtuin substrate). Together they target distinct mitochondrial aspects: SS-31 targets membrane structure; MOTS-c targets metabolic signaling; NAD+ targets electron transport and sirtuin regulation.

See MOTS-c deep dive and NAD+ longevity trial review.

SS-31: SS-31 guide, SS-31 clinical evidence, SS-31 cardiolipin deep dive. MOTS-c: MOTS-c guide, MOTS-c deep dive. NAD+: NAD+ guide, NAD+ longevity trial review. Context: mitochondria and aging research.